Medical Journal of Viral Hepatitis (MJVH) - Keyword Index
Home
Browse
Current Issue
By Issue
By Author
By Subject
Author Index
Keyword Index
Journal Info
About Journal
Aims and Scope
Editorial Board
Publication Ethics
Peer Review Process
Guide for Authors
Submit Manuscript
Contact Us
Login
Register
Home
Keyword Index
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
A
Acute; 2.2, Issue 2, 2018, Page 15-16
Acute kidney injury; 2.2, Issue 2, 2018, Page 7-14
Acute oesophageal variceal haemorrhage; 7.1, Issue 1, 2022, Page 1-7
Acute on chronic liver failure; 5.3, Issue 3, 2021, Page 27-31
Acute on chronic liver failure; (Articles in Press)
Alpha fetoprotein; 4.2, Issue 2, 2020, Page 69-73
Alpha fetoprotein; 6.2, Issue 2, 2022, Page 11-17
Alpha fetoprotein (AFP); 3.2, Issue 2, 2019, Page 75-79
Alpha-Methyldopa; 2.2, Issue 2, 2018, Page 15-16
Antigen Quantitation; 2.1, Issue 1, 2016, Page 1-11
APRI; 2.1, Issue 1, 2016, Page 1-8
Ascites and gram-negative enteric organisms; 3.1, Issue 1, 2018, Page 13-17
Ascitic fluid infections; 5.3, Issue 3, 2021, Page 1-7
B
B-cell monoclonal lymphocytosis; 3.1, Issue 1, 2018, Page 27-35
Bilharziasis; 1.2, Issue 2, 2016, Page 1-10
Blood transfusion; 5.2, Issue 2, 2021, Page 27-31
C
Carnett´s sign; 5.1, Issue 1, 2020, Page 33-40
Carolis disease; 3.1, Issue 1, 2018, Page 1-4
Castleman disease; 6.2, Issue 2, 2022, Page 1-3
Cellular carcinoma; 2.1, Issue 1, 2016, Page 1-11
Child score; 7.1, Issue 1, 2022, Page 21-32
Choledocholithiasis; (Articles in Press)
Cholelithiasis; (Articles in Press)
Cholestasis; 4.2, Issue 2, 2020, Page 53-55
Chronic hepatitis; 3.2, Issue 2, 2019, Page 57-64
Chronic hepatitis; 5.1, Issue 1, 2020, Page 7-12
Chronic hepatitis; (Articles in Press)
Chronic hepatitis B; 1.1, Issue 1, 2015, Page 1-9
Chronic hepatitis B; 2.1, Issue 1, 2016, Page 1-11
Chronic hepatitis B; 2.2, Issue 2, 2018, Page 17-23
Chronic hepatitis C; 1.2, Issue 2, 2016, Page 1-12
Chronic hepatitis C; 2.1, Issue 1, 2016, Page 1-8
Chronic hepatitis C; 2.1, Issue 1, 2016, Page 1-9
Chronic hepatitis C; 4.1, Issue 1, 2019, Page 45-52
Chronic hepatitis C; 6.3, Issue 3, 2022, Page 5-11
Chronic hepatitis C; 7.2, Issue 2, 2023, Page 9-14
Chronic hepatitis C virus; 2.2, Issue 2, 2018, Page 1-6
Chronic liver disease; 4.2, Issue 2, 2020, Page 57-61
Chronic liver disease; 7.2, Issue 2, 2023, Page 15-22
Chronic liver diseases; 6.3, Issue 3, 2022, Page 19-21
Cirrhosis; 3.1, Issue 1, 2018, Page 13-17
Cirrhosis; 4.1, Issue 1, 2019, Page 5-14
Cirrhosis; 4.1, Issue 1, 2019, Page 15-21
Cirrhosis; 4.2, Issue 2, 2020, Page 63-68
Cirrhosis; 5.2, Issue 2, 2021, Page 9-15
Cirrhosis; 5.2, Issue 2, 2021, Page 16-20
Coagulopathy; 5.2, Issue 2, 2021, Page 3-8
Coinfection; 1.1, Issue 1, 2015, Page 1-9
Colorectal carcinoma; 3.1, Issue 1, 2018, Page 19-25
Common bile duct stones; 4.2, Issue 2, 2020, Page 81-86
Complications; 3.2, Issue 2, 2019, Page 41-47
Coronavirus disease; 5.1, Issue 1, 2020, Page 3-5
Coronavirus disease; 5.2, Issue 2, 2021, Page 1-2
COVID-19; 5.1, Issue 1, 2020, Page 41-45
COVID-19; 5.2, Issue 2, 2021, Page 3-8
COVID-19; 7.2, Issue 2, 2023, Page 15-22
C reactive protein; 6.3, Issue 3, 2022, Page 12-18
Crohn’s disease and ulcerative colitis; 5.1, Issue 1, 2020, Page 19-24
Cytokeratin-18; 3.2, Issue 2, 2019, Page 65-74
D
DAAs therapy; 7.1, Issue 1, 2022, Page 21-32
DAA Treatment; 7.2, Issue 2, 2023, Page 9-14
Daclatasvir; 5.2, Issue 2, 2021, Page 32-39
D-Dimer; 5.2, Issue 2, 2021, Page 3-8
Diabetes mellitus; 6.1, Issue 1, 2021, Page 38-45
Direct acting antiviral; 5.2, Issue 2, 2021, Page 9-15
Direct-acting antiviral agents; 4.2, Issue 2, 2020, Page 69-73
Direct-acting antiviral agents; 5.1, Issue 1, 2020, Page 7-12
Direct-acting antiviral agents; (Articles in Press)
Direct-acting antiviral agents; 6.1, Issue 1, 2021, Page 46-53
Direct-acting antiviral agents; 6.2, Issue 2, 2022, Page 11-17
Direct acting antivirals; 5.2, Issue 2, 2021, Page 21-26
Dual infection; 1.1, Issue 1, 2015, Page 1-9
E
Elastography; 1.2, Issue 2, 2016, Page 1-10
Encephalitis; 7.3, Issue 3, 2023, Page 15-17
Endoscopic retrograde cholangiopancreatography; 4.2, Issue 2, 2020, Page 81-86
Endoscopic retrograde cholangiopancreatography; (Articles in Press)
Endoscopic ultrasound; 4.2, Issue 2, 2020, Page 81-86
Endoscopic ultrasound; (Articles in Press)
Endoscopy; 5.1, Issue 1, 2020, Page 41-45
Endoscopy; 6.2, Issue 2, 2022, Page 25-30
Entecavir; 7.1, Issue 1, 2022, Page 13-14
Enzyme replacement therapy and hepatosplenomegaly; 6.2, Issue 2, 2022, Page 6-10
Eosinophilic gastroenteritis; 3.2, Issue 2, 2019, Page 37-40
Epstein-Barr virus; 7.3, Issue 3, 2023, Page 15-17
Esophageal varices; 1.2, Issue 2, 2016, Page 1-10
Esophageal varices; 6.2, Issue 2, 2022, Page 25-30
F
Fatty liver index; 5.1, Issue 1, 2020, Page 25-32
Fatty liver index; (Articles in Press)
FIB-4; 1.2, Issue 2, 2016, Page 1-10
FIB-4; 2.1, Issue 1, 2016, Page 1-8
FIB-4 score; 5.1, Issue 1, 2020, Page 25-32
FIB-4 score; (Articles in Press)
Fibrofast (FIB-5); 1.2, Issue 2, 2016, Page 1-10
FibroScan; 2.1, Issue 1, 2016, Page 1-8
FibroScan; 2.1, Issue 1, 2016, Page 1-9
FibroScan; 4.1, Issue 1, 2019, Page 45-52
Fulminant hepatitis; 7.1, Issue 1, 2022, Page 13-14
G
Gastric variceal bleeding; 5.3, Issue 3, 2021, Page 14-21
Gastrointestinal bleeding; 5.1, Issue 1, 2020, Page 41-45
Gaucher disease; 6.2, Issue 2, 2022, Page 6-10
Genetics; 1.2, Issue 2, 2016, Page 1-12
Genotype 4; 1.2, Issue 2, 2016, Page 1-12
Genotype 4; 2.1, Issue 1, 2016, Page 1-8
GLP1-RAs; 5.1, Issue 1, 2020, Page 25-32
GLP1-RAs; (Articles in Press)
H
HBV; 5.3, Issue 3, 2021, Page 22-26
HBV genotype D; 1.1, Issue 1, 2015, Page 1-14
HBV-HCV coinfection; 4.2, Issue 2, 2020, Page 63-68
HBV Reactivation; 4.2, Issue 2, 2020, Page 63-68
HCV; 5.1, Issue 1, 2020, Page 7-12
HCV; (Articles in Press)
HCV; 5.3, Issue 3, 2021, Page 22-26
HCV; 6.1, Issue 1, 2021, Page 17-23
HCV; 6.1, Issue 1, 2021, Page 24-31
HCV; 7.1, Issue 1, 2022, Page 21-32
Health related quality of life; 7.2, Issue 2, 2023, Page 9-14
Hemodialysis; 5.3, Issue 3, 2021, Page 22-26
Hemoglobin; 5.2, Issue 2, 2021, Page 21-26
Hepatic artery resistive index; 7.2, Issue 2, 2023, Page 1-8
Hepatic failure; 5.3, Issue 3, 2021, Page 27-31
Hepatic failure; (Articles in Press)
Hepatic fibrosis; 1.2, Issue 2, 2016, Page 1-12
Hepatitis; 2.2, Issue 2, 2018, Page 15-16
Hepatitis; 7.3, Issue 3, 2023, Page 15-17
Hepatitis A vaccination; 1.1, Issue 1, 2015, Page 1-9
Hepatitis B Infection; 5.3, Issue 3, 2021, Page 27-31
Hepatitis B Infection; (Articles in Press)
Hepatitis B Surface; 2.1, Issue 1, 2016, Page 1-11
Hepatitis B virus; 1.1, Issue 1, 2015, Page 1-9
Hepatitis B virus; 3.2, Issue 2, 2019, Page 49-56
Hepatitis B virus; 4.2, Issue 2, 2020, Page 63-68
Hepatitis B virus; 5.2, Issue 2, 2021, Page 27-31
Hepatitis B virus; 6.1, Issue 1, 2021, Page 38-45
Hepatitis C Genotype 4; 1.2, Issue 2, 2016, Page 1-10
Hepatitis C genotyping; 5.1, Issue 1, 2020, Page 1-2
Hepatitis C virus; 1.1, Issue 1, 2015, Page 1-11
Hepatitis C virus; 2.1, Issue 1, 2016, Page 1-8
Hepatitis C virus; 4.2, Issue 2, 2020, Page 69-73
Hepatitis C virus; 5.1, Issue 1, 2020, Page 1-2
Hepatitis C virus; 5.1, Issue 1, 2020, Page 7-12
Hepatitis C virus; (Articles in Press)
Hepatitis C virus; 5.3, Issue 3, 2021, Page 8-13
Hepatitis C virus; 6.1, Issue 1, 2021, Page 38-45
Hepatitis C virus; 6.1, Issue 1, 2021, Page 46-53
Hepatitis C virus; 6.2, Issue 2, 2022, Page 11-17
Hepatitis C Virus Genotype 4; 2.1, Issue 1, 2016, Page 1-14
Hepatocellular carcinoma; 4.1, Issue 1, 2019, Page 35-43
Hepatocellular carcinoma; 5.2, Issue 2, 2021, Page 9-15
Hepatocellular carcinoma; 6.2, Issue 2, 2022, Page 11-17
Hepatocellular carcinoma; 6.2, Issue 2, 2022, Page 18-24
Hepatocellular carcinoma; 7.1, Issue 1, 2022, Page 15-20
Hepatocellular carc-inoma; 5.1, Issue 1, 2020, Page 1-2
Hepatocellular carcinoma; 6.1, Issue 1, 2021, Page 38-45
Hepatocellular carcinoma (HCC); 3.2, Issue 2, 2019, Page 75-79
Hepatopulmonary syndrome; 3.1, Issue 1, 2018, Page 5-12
Hepatorenal syndrome; 2.2, Issue 2, 2018, Page 7-14
Hesperidin; 7.1, Issue 1, 2022, Page 15-20
Human albumin; 5.1, Issue 1, 2020, Page 13-18
Hyaluronic acid; 2.1, Issue 1, 2016, Page 1-14
Hyaluronic acid vascular; 2.1, Issue 1, 2016, Page 1-14
Hyperthyroidism and antithyroid drugs; 4.2, Issue 2, 2020, Page 53-55
Hypoalbuminemia; 2.2, Issue 2, 2018, Page 25-29
I
IFN- γ gene polymorphism; 6.1, Issue 1, 2021, Page 24-31
Infection; 4.1, Issue 1, 2019, Page 5-14
Infection; 4.2, Issue 2, 2020, Page 57-61
Insulin Resistance; 6.1, Issue 1, 2021, Page 4-9
Interleukin-28B; 1.2, Issue 2, 2016, Page 1-12
J
K
L
Lipid profile; 5.2, Issue 2, 2021, Page 21-26
Liver Biopsy; 1.2, Issue 2, 2016, Page 1-10
Liver Biopsy; 2.1, Issue 1, 2016, Page 1-9
Liver Biopsy; 3.1, Issue 1, 2018, Page 27-35
Liver cirrhosis; 2.2, Issue 2, 2018, Page 7-14
Liver cirrhosis; 4.1, Issue 1, 2019, Page 23-33
Liver cirrhosis; 4.2, Issue 2, 2020, Page 75-80
Liver cirrhosis; 6.2, Issue 2, 2022, Page 18-24
Liver cirrhosis; 6.2, Issue 2, 2022, Page 25-30
Liver cirrhosis; 6.3, Issue 3, 2022, Page 29-31
Liver cirrhosis; 7.1, Issue 1, 2022, Page 1-7
Liver fibrosis; 1.2, Issue 2, 2016, Page 1-10
Liver fibrosis; 1.2, Issue 2, 2016, Page 1-10
Liver fibrosis; 2.1, Issue 1, 2016, Page 1-14
Liver fibrosis; 2.2, Issue 2, 2018, Page 17-23
Liver fibrosis; 3.1, Issue 1, 2018, Page 27-35
Liver fibrosis; 4.1, Issue 1, 2019, Page 45-52
Liver fibrosis parameters; 7.1, Issue 1, 2022, Page 21-32
Liver Stiffness; 6.3, Issue 3, 2022, Page 5-11
Liver stiffness measurement; 4.1, Issue 1, 2019, Page 45-52
Liver stiffness measurement; 7.2, Issue 2, 2023, Page 1-8
Liver transplantation; 3.2, Issue 2, 2019, Page 41-47
Lower gastrointestinal bleeding; 3.1, Issue 1, 2018, Page 19-25
M
Medicare and Medicaid Services; 7.3, Issue 3, 2023, Page 7-14
Melatonin; 3.2, Issue 2, 2019, Page 75-79
MELD; 7.1, Issue 1, 2022, Page 21-32
Metabolic; 6.2, Issue 2, 2022, Page 4-5
Metabolic associated fatty liver disease; 6.2, Issue 2, 2022, Page 4-5
Metabolic associated fatty liver disease; 6.3, Issue 3, 2022, Page 22-28
Metabolic dysfunction-associated fatty liver disease; 6.1, Issue 1, 2021, Page 4-9
Mixed ascites; 4.2, Issue 2, 2020, Page 75-80
N
NAFLD; 3.2, Issue 2, 2019, Page 65-74
NAFLD; 5.1, Issue 1, 2020, Page 25-32
NAFLD; (Articles in Press)
NAFLD fibrosis score; 7.2, Issue 2, 2023, Page 1-8
Nano zinc oxide; 7.1, Issue 1, 2022, Page 8-12
NASH; 3.2, Issue 2, 2019, Page 65-74
Nomenclature; 6.2, Issue 2, 2022, Page 4-5
Non-alcoholic fatty liver disease; 6.1, Issue 1, 2021, Page 4-9
Non-alcoholic fatty liver disease; 6.1, Issue 1, 2021, Page 32-37
Nonalcoholic fatty liver disease; 6.2, Issue 2, 2022, Page 4-5
Nonalcoholic fatty liver disease; 7.2, Issue 2, 2023, Page 1-8
Non-Coding RNA ZFAS1; 6.2, Issue 2, 2022, Page 18-24
Non-Hodgkin lymphoma; 4.1, Issue 1, 2019, Page 1-4
Noninvasive markers; 2.2, Issue 2, 2018, Page 17-23
Non-invasive measures; 1.2, Issue 2, 2016, Page 1-10
Nucleoside/nucleotide analogues and hepatitis B vaccine; 3.2, Issue 2, 2019, Page 49-56
Nucleos(t)ide analogues and dental practice; 4.2, Issue 2, 2020, Page 63-68
Nutritional Status; 3.2, Issue 2, 2019, Page 41-47
O
Occult HCV Infection; 5.1, Issue 1, 2020, Page 7-12
Occult HCV Infection; (Articles in Press)
Oesophageal varices; 7.1, Issue 1, 2022, Page 1-7
Oral microbiome; 6.3, Issue 3, 2022, Page 19-21
Oxidative Stress; 7.1, Issue 1, 2022, Page 15-20
P
Pathology; 1.1, Issue 1, 2015, Page 1-14
Pediatrics; 6.1, Issue 1, 2021, Page 17-23
Periodontitis; 4.2, Issue 2, 2020, Page 57-61
PMN count and hepatorenal syndrome (HRS); 2.2, Issue 2, 2018, Page 25-29
Polymerase inhibitors; 1.1, Issue 1, 2015, Page 1-11
Portal Hypertension; 4.1, Issue 1, 2019, Page 15-21
Pregnancy; 2.2, Issue 2, 2018, Page 15-16
Pregnancy; 4.2, Issue 2, 2020, Page 63-68
Protease inhibitors; 1.1, Issue 1, 2015, Page 1-11
Q
Quantitative multi-parametric magnetic resonance imaging; 6.1, Issue 1, 2021, Page 32-37
R
Receptor interacting protein kinase-1; 7.1, Issue 1, 2022, Page 15-20
Recurrence; 2.2, Issue 2, 2018, Page 25-29
Ribavirin; 2.1, Issue 1, 2016, Page 1-8
Ribavirin; 5.2, Issue 2, 2021, Page 32-39
S
Sarcopenia and pre-sarcopenia; 4.1, Issue 1, 2019, Page 23-33
SARS-CoV-2; 5.1, Issue 1, 2020, Page 3-5
SBP; 2.2, Issue 2, 2018, Page 25-29
Schistosomiasis; 3.2, Issue 2, 2019, Page 57-64
Schistosomiasis; 6.1, Issue 1, 2021, Page 38-45
Score; 2.1, Issue 1, 2016, Page 1-14
Seroepidemiology; 5.3, Issue 3, 2021, Page 22-26
Serum ALT; 1.1, Issue 1, 2015, Page 1-9
Serum bilirubin; 1.1, Issue 1, 2015, Page 1-9
Sofosbuvir; 5.2, Issue 2, 2021, Page 32-39
Sofosbuvir plus; 2.1, Issue 1, 2016, Page 1-8
Spontaneous Bacterial Peritonitis; 3.1, Issue 1, 2018, Page 13-17
Spontaneous Bacterial Peritonitis; 5.1, Issue 1, 2020, Page 13-18
Spontaneous Bacterial Peritonitis; 5.2, Issue 2, 2021, Page 16-20
Spontaneous Bacterial Peritonitis; 5.3, Issue 3, 2021, Page 1-7
Spontaneous Bacterial Peritonitis; 6.3, Issue 3, 2022, Page 12-18
Spontaneous Bacterial Peritonitis; 7.1, Issue 1, 2022, Page 1-7
Spontaneous Bacterial Peritonitis; 7.3, Issue 3, 2023, Page 7-14
Spontaneous bacterial peritonitis and acute on top of chronic liver failure; 4.1, Issue 1, 2019, Page 5-14
Superinfection; 1.1, Issue 1, 2015, Page 1-9
Sustained viral response; 1.1, Issue 1, 2015, Page 1-11
Sustained virologic response; 4.2, Issue 2, 2020, Page 69-73
Sustained virologic response; 6.1, Issue 1, 2021, Page 1-3
Sustained virologic response; 6.1, Issue 1, 2021, Page 46-53
Sustained virologic response; 6.2, Issue 2, 2022, Page 11-17
T
Teenagers; 1.1, Issue 1, 2015, Page 1-9
Terlipressin; 2.2, Issue 2, 2018, Page 7-14
Tertiary peritonitis; 6.3, Issue 3, 2022, Page 29-31
Therapy; 1.1, Issue 1, 2015, Page 1-14
Thioredoxin; 5.2, Issue 2, 2021, Page 9-15
Togo; 5.3, Issue 3, 2021, Page 8-13
Togo; 5.3, Issue 3, 2021, Page 22-26
Transient elastography; 2.1, Issue 1, 2016, Page 1-9
Transient elastography; 2.2, Issue 2, 2018, Page 17-23
Transient elastography; 4.1, Issue 1, 2019, Page 45-52
Transient elastography; 6.3, Issue 3, 2022, Page 22-28
Treatment; 1.1, Issue 1, 2015, Page 1-11
Treatment-naïve; 2.1, Issue 1, 2016, Page 1-8
Treatment response; 2.1, Issue 1, 2016, Page 1-11
U
Ulcerative colitis and piles; 3.1, Issue 1, 2018, Page 19-25
Undiagnosed chronic abdominal pain; 5.1, Issue 1, 2020, Page 33-40
V
Vascular endothelial growth; 2.1, Issue 1, 2016, Page 1-14
Viral load; 1.1, Issue 1, 2015, Page 1-14
W
X
Y
Z